FINWIRES · TerminalLIVE
FINWIRES

Roth Capital Initiates Castle Biosciences at Buy

By

Castle Biosciences (CSTL) has an average rating of buy and mean price target of $43.56, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles